Shimada A, Suzuki S, Satomura A, Oikawa Y. Etiology of Exocrine Enzyme Elevation in Ketosis-prone Type 2 Diabetes and Type 1 diabetes. The 85th ADA scientific meeting, 2025/6/20-23, Chicago, Illinois, USA.
Haisa A, Satomura A, Oikawa Y, Shimada A. High Anti-glutamic Acid Decarboxylase Autoantibody Titers may be Associated with High Disease Activity of Slowly Progressive Type 1 Diabetes Mellitus. The 85th ADA scientific meeting, 2025/6/20-23, Chicago, Illinois, USA.
Satomura A, Oikawa Y, Nakanishi S, Suzuki S, Shimada A. Significance of Glucagon in the Development of Ketosis-prone Type 2 diabetes. The 85th ADA scientific meeting, 2025/6/20-23, Chicago, Illinois, USA.
Oikawa Y, Fujisawa M, Satomura A, Shimada A. Immunological Role of Hybrid Insulin Peptide in Type 1 Diabetes in Asia. The 85th ADA scientific meeting, 2025/6/20-23, Chicago, Illinois, USA.
Shimada A, Suzuki S, Satomura A, Oikawa Y. Carbonic anhydrase 2 might be a target exocrine tissue antigen in Ketosis-prone type 2 diabetes with HLA DRB1*08:03. The 20th Immunology of Diabetes Society Conference, 2024/11/4-8, Bruges, Belgium.
Oikawa Y, Fujisawa M, Satomura A, Shimada A. Immunological significance of immune responses to hybrid insulin peptide in type 1 diabetes in Asia. The 20th Immunology of Diabetes Society Conference, 2024/11/4-8, Bruges, Belgium.
Shimada A. Insulin treatment in Japan -from history to future prospects-. Challenge of Type 1 Diabetes Treatment and Insulin Supply in WPR. The IDF-WPR Congress 2023 / 15th Scientific Meeting of AASD, 2023/1/21-23, Kyoto, Japan.
Satomura A, Suzuki S, Haisa A, Oikawa Y, Shimada A. Insulin peptide reactive T cells may reflect disease activity in ketosis-prone Type 2 diabetes. The 80th ADA scientific meeting, 2020/6/12-16, Virtual meeting, Chicago, Illinois, USA.
Oikawa Y, Satomura A, Haisa A, Suzuki S, Shimada A. Immune Responses to Insulin B:9-23–Related Peptides Were Observed in Fulminant Type 1 Diabetes. The 80th ADA scientific meeting, 2020/6/12-16, Virtual meeting, Chicago, Illinois, USA.
Shimada A, Satomura A, Haisa A, Oikawa Y. Higher frequency of HLA DRB1*08:03 and DRB1*04:01 were observed in A-beta+ ketosis-prone type 2 diabetes in Japanese subjects. The 80th ADA scientific meeting, 2020/6/12-16, Virtual meeting, Chicago, Illinois, USA.
Kawasaki T, Ueda S, Ichinose Y, Hirokawa E, Shimada H, Sugitani I, Sano H, Hasebe T, Takahashi T, Osaki A, Saeki T, Oikawa Y, Inoue I, Noda M, Shimada A, Nagashima Y, Kamada K, Kanno S, Urano M, Kuroda M, Utsumi T, Hayashi T. High-molecular-weight insulin-like growth factor 2 secreting phyllodes tumor of the breast presenting as a hypoglycemic attack. The 31st European Congress of Pathology, 2019/9/7-11, Nice, France.
Shimada A, Satomura A, Haisa A, Oikawa Y. Significance of anti-insulin immune responses in autoimmune diabees with HLA DR9. The 79th ADA scientific meeting, 2019/6/7-11, San Francisco, California, USA.
Oikawa Y, Kondo T, Shimada A, Seino Y, Kitaoka M. A considerable mismatch of measurements between radioimmunoassay and enzyme-linked immunosorbent assay tests for anti-glutamic acid decarboxylase antibody. The 79th ADA scientific meeting, 2019/6/7-11, San Francisco, California, USA.
Shimada A. Type 1 diabetes–pathophysiology and diagnosis. The 18th annual ISPAD Science School for Physicians. 2018/9-30-10/3, Shonan Village Center, Kanagawa, Japan.
Oikawa Y, katsuki T, Kawai T, Shimada A. A cut-off value for anti-GAD antibody ELISA test for predicting future insulin dependency in SPIDDM may not exist. The 78th ADA scientific meeting, 2018/6/22-26, Orlando, Florida, USA.
Noda M. The Japanese experience (in symposium “East-West Forum: diabetes outcome trends”). The 53rd Annual Meeting of the European Association for the Study of Diabetes, 2017/9/11-15, Lisbon, Portugal.
Noda M. Clinical practice guideline for the treatment of diabetes in Japan – concept and essence (in symposium “International clinical practice guidelines for diabetes mellitus; NICE, IDF, AACE, JDS, and KDA”). 2017 International Congress of Diabetes & Metabolism, 2017/9/28-30, Seoul, Korea.
Oikawa Y, Yajima K, Hashiguchi A, Shimada A. Immunological Significance of CD4+ T-Cells in Acute-Onset Type 1 Diabetes Characterized by CD4+ T Cells-Dominant Insulitis. The 77th ADA scientific meeting, 2017/6/9-13, San Diego, California, USA.
Shimada A, Satomura A, Miyashita Y, Oikawa Y, Inoue I, Noda M. Insulin Peptide Reactive T-Cells Detected in Ketosis-Prone Type 2 Diabetes. The 77th ADA scientific meeting, 2017/6/9-13, San Diego, California, USA.
Hatano M. Prevalence of Hypertension in Japanese Diebetes Mellitus with Pre‐Hypertension and Normotension. Th 4th International Conference on PreHypertension, Hypertension and Cardio Metabolic Syndrome, 2016/3/3-6, Venice, Italy.
Kabeya Y, Uchida J, Oikawa Y, Shimada A, Atsumi Y. Factors Affecting Length of Consultation Time in Diabetes Practice. The 76th ADA scientific meeting, 2016/6/10-14, New Orleans, Louisiana, USA.
Oikawa Y, Matsushita M, James EA, Hattori Y, Shimada A. GAD-related Peptide-specific CD4 T Cells Were Detected in Patients with Type 1 Diabetes with HLA-DRB1*09:01. The 76th ADA scientific meeting, 2016/6/10-14, New Orleans, Louisiana, USA.
Shimada A, Oikawa Y, Matsushita M, Hattori Y. Serum CXCL10 Reflects Insulin-specific T Cell Response in Type 1 Diabetes. The 76th ADA scientific meeting, 2016/6/10-14, New Orleans, Louisiana, USA.